Compare TSBK & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSBK | CERS |
|---|---|---|
| Founded | 1915 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.1M | 276.0M |
| IPO Year | 1997 | 1996 |
| Metric | TSBK | CERS |
|---|---|---|
| Price | $41.35 | $1.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 38.7K | ★ 1.7M |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | 21.93 | ★ 27.27 |
| EPS | ★ 1.04 | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | N/A | $19.95 |
| Revenue Next Year | N/A | $8.84 |
| P/E Ratio | $39.92 | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $28.20 | $1.15 |
| 52 Week High | $42.62 | $2.96 |
| Indicator | TSBK | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 77.06 | 54.52 |
| Support Level | $37.51 | $1.93 |
| Resistance Level | N/A | $2.26 |
| Average True Range (ATR) | 0.74 | 0.09 |
| MACD | 0.34 | 0.04 |
| Stochastic Oscillator | 94.25 | 96.88 |
Timberland Bancorp Inc is a bank holding company for Timberland Bank. The bank offers banking services including personal checking and savings accounts, debit cards, health savings accounts, online and mobile banking, online bill pay, 24-hour phone banking, and Zelle. Business services include business checking accounts, online banking, remote deposit, ACH transactions, Autobooks, and insured cash sweep services. The bank also provides lending services such as personal credit cards, home loans, home equity borrowing, construction loans, and SBA loans. In addition, it offers loans to real estate, including residential and commercial real estate, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.